Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 2/8/2020
SIETES contiene 93072 citas

 1 a 20 de 65 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, Wimberley T, Thygesen M, Bang Madsen K, Timmerman A, Schendel D, McGrath JJ, Mortensen PB, Pedersen CB. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry 2019:20 de noviembre. [Ref.ID 103222]
3. Cita con resumen
Marston L, Nazareth I, Petersen I, Osborn DPJ. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2015;4:1-11. [Ref.ID 98973]
4. Cita con resumen
Anónimo. Lisdexamfetamine /Vyvanse) for binge eating disorder. Med Lett Drugs Ther 2015;57:42. [Ref.ID 98884]
5. Cita con resumen
Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry 2013;28:7-20. [Ref.ID 94663]
6. Cita con resumen
Kuehn BM. Off-label atypical antipsychotics. JAMA 2012;308:1198. [Ref.ID 93799]
7. Cita con resumen
Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. A systematic review and meta-analysis. JAMA 2011;306:1359-69. [Ref.ID 91219]
8. Cita con resumen
Anónimo. DSM-5: diagnosis of mental disorders. Lancet 2010;376:390. [Ref.ID 89067]
9. Cita con resumen
Moberly T. Cymbalta approved for fibromyalgia. Scrip 2008;3372:14. [Ref.ID 83352]
10. Cita con resumen
Morris K. Research on psychedelics moves into the mainstream. Lancet 2008;371:1491-2. [Ref.ID 82795]
12.Tiene citas relacionadas
Bridge JA, Birmaher B, Brent DA. Benefits and harms of pediatric antidepressant medications. In reply. JAMA 2007;298:627. [Ref.ID 80872]
13.Tiene citas relacionadas
Edwards JL, Midha CK. Benefits and harms of pediatric antidepressant medications. JAMA 2007;298:626-7. [Ref.ID 80871]
14.Tiene citas relacionadas
Waslick B. Benefits and harms of pediatric antidepressant medications. JAMA 2007;298:626. [Ref.ID 80870]
15.Tiene citas relacionadas Cita con resumen
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. A meta-analysis of randomized controlled trials. JAMA 2007;297:1683-96. [Ref.ID 79798]
Lovell K, Cox D, Haddock G, Jones C, Raines D, Garvey R, Roberts C, Hadley S. Telephone administered cognitive behaviour therapy for treatment of obsessive compulsive disorder: randomised controlled non-inferiority trial. BMJ 2006;333:883-6. [Ref.ID 78439]
17. Cita con resumen
Applbaum K. Pharmaceutical marketing and the invention of the medical consumer. PLOS Medicine 2006;3:189. [Ref.ID 78352]
Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive disorder. BMJ 2006;333:424-9. [Ref.ID 77887]
19. Cita con resumen
Schlaepfer TE, Lieb K. Deep brain stimulation for treatment of refractory depression. Lancet 2005;366:1420-2. [Ref.ID 75170]
Van Ameringen M, Mancini C, Pipe B, Bennett M. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004;64:2199-220. [Ref.ID 72812]
Seleccionar todas
 1 a 20 de 65 siguiente >>